Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2300072589Phase 2Recruiting
Phase 2, open-label, single-arm trial of pemigatinib in glioma, sponsored by Beijing Sanbo Brain Hospital. Primary endpoint: objective response rate. Started Jun 2023; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2300072589.